ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
6.43
-0.39 (-5.72%)
At close: Mar 28, 2025, 4:00 PM
6.31
-0.12 (-1.83%)
Pre-market: Mar 31, 2025, 5:08 AM EDT
ABIVAX Société Anonyme Revenue
In the year 2024, ABIVAX Société Anonyme had annual revenue of 10.79M EUR with 135.94% growth. ABIVAX Société Anonyme had revenue of 4.01M in the half year ending December 31, 2024, with 78.20% growth.
Revenue (ttm)
10.79M EUR
Revenue Growth
+135.94%
P/S Ratio
36.99
Revenue / Employee
176,918 EUR
Employees
61
Market Cap
413.31M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.79M | 6.22M | 135.94% |
Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
Dec 31, 2020 | 14.00K | 21.00K | -300.00% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ABVX News
- 4 days ago - Abivax publishes financial reports with the French and U.S. securities regulatory agencies - GlobeNewsWire
- 7 days ago - Abivax Announces Full Year 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 - GlobeNewsWire
- 2 months ago - Abivax Publishes 2025 Financial Calendar - GlobeNewsWire
- 2 months ago - Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress - GlobeNewsWire
- 2 months ago - Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment - GlobeNewsWire
- 3 months ago - Abivax Announces a Change to the Composition of its Board of Directors - GlobeNewsWire
- 4 months ago - Abivax Establishes an At-the-Market (ATM) Program on Nasdaq - GlobeNewsWire